Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
While there is a long and growing list of FDA approved chemotherapy regimens for multiple myeloma, several of these chemos cause the multiple myeloma side effect called peripheral neuropathy/nerve damage aka chemotherapy-induced peripheral neuropathy aka CIPN.
According to the study linked below 65% of MMers report grade 2-3 PN.
Conventional oncology tells patients that PN goes away once therapy ends but my nerve damage has progressively worsened over the years. I live with increasing numbness. I’ll take numbness over the debilitating burning pain that many myeloma survivors talk about.
The best way to avoid chemotherapy-induced peripheral neuropathy (CIPN) is to prevent this side-effect in the first place. If you already have CIPN, learn more about pain therapy.
The other study linked below cites cannabinoids as nerve pain therapy. The trick with CBD oil is to figure out:
I am both a long-term MM survivor and MM cancer coach. I live an evidence-based, non-toxic, anti-Myeloma lifestyle through nutrition, supplementation, bone health, lifestyle and mind-body therapies.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Are you experiencing chemotherapy-induced nerve damage? Scroll to the bottom of the page, post a question or a comment and I will reply to you ASAP.
“Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients’ health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN…
Overall, 65 % of patients reported grade 2-3 neuropathy according to the ICPNQ…
RESLTS: The psychometric analyses showed a Cronbach’s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2-3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.
CONCLUSIONS: CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.
“Summary-We have here presented an overview of pharmacotherapy for neuropathic pain. Neuropathic pain is generally intractable and does not quickly respond to evidence‐supported medications in many cases. However, therapeutic options have expanded in the past few years, due to approval and expansion of the indications for various drugs.
In addition, recently approved drugs generally have a wider therapeutic dose range than in the past, given the increasing opportunities for global studies. These situations enable adequate therapy, depending on the extent of the symptoms and interindividual differences, but also require careful observation for determining the optimal dose while considering therapeutic efficacy and safety in individual patients. Furthermore, because pain perception varies with culture and ethnicity, practice‐based research will be required for establishing evidence specific to Japanese patients.
It may not be easy to meet the needs of patients suffering from neuropathic pain fully, but physicians will do well with full knowledge and ingenious use of the available therapeutic drugs.”
“Treatment options for neuropathic pain have limited efficacy and use is fraught with dose-limiting adverse effects… Exogenous cannabinoids have been demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for therapeutic use in human neuropathic pain conditions..”
Results: Out of the 22 patients, 15 had CNP secondary to chemotherapy-induced peripheral neuropathy. Compared with baseline, there was a significant reduction in numeric pain rating scale (p < 0.001). Additionally, 76.5% of patients (n = 13) were considered to be responders to LIFU therapy.
Conclusion: LIFU therapy may be a viable treatment modality in the management of CNP, specifically chemotherapy-induced peripheral neuropathy, with a minimal side effect profile. Larger, prospective studies with a structured protocol are necessary…”